Prediction of Response to Treatment by Gene Expression Profiling of Peripheral Blood in Patients with Microscopic Polyangiitis

Ishizu Akihiro; Tomaru Utano; Murai Taichi; Yamamoto Tomohiro; Atsumi Tatsuya; Yoshiki Takashi; Yumura Wako; Yamagata Kunihiro; Yamada Hidehiro; Kumagai Shunichi; Kurokawa Manae S.; Suka Machi; Makino Hirofumi; Ozaki Shoichi

タイトル	en Prediction of Response to Treatment by Gene Expression Profiling of Peripheral Blood in Patients with Microscopic Polyangiitis
作成者	en Ishizu, Akihiro NRID 1000060321957 en Tomaru, Utano NRID 1000020360901 en Murai, Taichi en Yamamoto, Tomohiro en Atsumi, Tatsuya NRID 1000020301905 en Yoshiki, Takashi NRID 1000060220612 en Yumura, Wako en Yamagata, Kunihiro NRID 1000090312850 en Yamada, Hidehiro NRID 1000000174730 en Kumagai, Shunichi NRID 1000000153346 en Kurokawa, Manae S. NRID 1000090301598 en Suka, Machi NRID 1000030339858 en Makino, Hirofumi NRID 1000050165685 en Ozaki, Shoichi NRID 1000000231233
アクセス権	open access
権利情報	http://creativecommons.org/licenses/by/3.0/ en Creative Commons Attribution 3.0 Unported
主題	NDC 491
内容注記	Abstract en The JMAAV study was an open-labeled prospective clinical trial, which proposed severity-based treatment protocols for patients with microscopic polyangiitis (MPA). The results suggest that the proposed protocols are useful (remission rate: 89.4%), but are also indicative of relapse or patient demise regardless of the treatment (recurrence rate: 19.0%; mortality rate: 10.6%). The aim of this study is to develop the method to predict response to the treatment in patients with MPA. In the present study, transcriptome analysis was performed using peripheral blood from patients enrolled in the JMAAV study before and 1-week after the beginning of treatment. The gene expression profile before treatment was not directly related to the response to the treatment. However, when the samples from 9 patients with good response (persistent remission for 18 months) were examined, the expression of 88 genes was significantly altered by the treatment. Thirty statistically reliable genes were selected, and then the alteration of expression by the treatment was examined among 22 patients, including 17 with good response, which was defined as persistent remission for 18 months and 5 with poor response, which was defined as relapse after remission or no remission. Discrimination analysis between the alteration of expression of the 30 genes by the treatment and the response identified a combination of 16 genes as the most valuable gene set to predict the response to the treatment. This preliminary study identified IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1, DEFA1/DEFA3, DEFA4, and COL9A2 as the important genes that can predict the response to the treatment in patients with MPA at an early point during the therapy.
出版者	en Public Library of Science
日付	Issued2013-05-17
言語	eng
資源タイプ	journal article
出版タイプ	VoR
資源識別子	HDL http://hdl.handle.net/2115/53034
関連	isIdenticalTo DOI https://doi.org/10.1371/journal.pone.0063182
収録誌情報	PISSN 1932-6203 en PLoS One 巻8 号5 開始ページe63182
ファイル	fulltext journal.pone.0063182.pdf 490.63 KB (application/pdf) Issued2013-05-17
コンテンツ更新日時	2023-07-26